Shares of** Eli Lilly **(LLY +2.87%) rose to a new all-time high on Tuesday, following upbeat analyst remarks.
禮來（LLY +2.87%）股價週二創下歷史新高，受分析師樂觀評論帶動。
Image source: Getty Images.
圖片來源：Getty Images。
Getting more bullish
更加看漲
JPMorgan analyst Chris Schott reiterated his overweight (read: buy) rating on Eli Lilly's stock and boosted his share price target from $1,300 to $1,400.
Even after today's gains, JPMorgan's new price forecast implies potential returns of over 13% for investors who buy Eli Lilly's shares now.
即使在今日漲勢後，摩根大通的新價格預測仍意味著現在買入禮來股票的投資者可能獲得超過13%的回報。
Expand
展開
NYSE: LLY
紐約證券交易所：LLY
Eli Lilly
禮來公司
Today's Change
今日變動
(2.87%) $34.47
(2.87%) 34.47美元
Current Price
目前價格
$1,234.53
1,234.53美元
Key Data Points
關鍵數據點
Market Cap
市值
$1.1TMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
The healthcare titan's market capitalization has ballooned to more than $1.1 trillion, driven by the blockbuster success of its popular GLP-1 drugs, Mounjaro and Zepbound.
Schott predicts that the rapid expansion of the U.S. weight-loss drug market and strong growth in international markets will drive Eli Lilly's sales and profits sharply higher.
肖特預測，美國減肥藥市場的快速擴張以及國際市場的強勁增長將推動禮來的銷售額和利潤大幅上升。
In turn, Schott expects the medicine maker's earnings to exceed consensus estimates when it reports its second-quarter financial results on Aug. 5.
反過來，肖特預期這家藥廠在8月5日公布第二季財報時，其獲利將超越市場共識預期。
Additional growth catalysts
額外成長催化劑
The obesity drug market is set to grow even larger. On July 1, the new GLP-1 Bridge program made Zepbound and Foundayo available to eligible Medicare patients for as low as $50 per month.
With an estimated 20 million Medicare patients potentially meeting the criteria for obesity drugs, there's a good chance JPMorgan's $1,400 target price for Eli Lilly's shares proves conservative.
為何禮來藥廠股價今日攀升至歷史新高
Shares of** Eli Lilly **(LLY +2.87%) rose to a new all-time high on Tuesday, following upbeat analyst remarks.
禮來（LLY +2.87%）股價週二創下歷史新高，受分析師樂觀評論帶動。
Image source: Getty Images.
圖片來源：Getty Images。
Getting more bullish
更加看漲
JPMorgan analyst Chris Schott reiterated his overweight (read: buy) rating on Eli Lilly's stock and boosted his share price target from $1,300 to $1,400.
摩根大通分析師克里斯·肖特重申對禮來股票的超配（即買入）評級，並將目標股價從1,300美元上調至1,400美元。
Even after today's gains, JPMorgan's new price forecast implies potential returns of over 13% for investors who buy Eli Lilly's shares now.
即使在今日漲勢後，摩根大通的新價格預測仍意味著現在買入禮來股票的投資者可能獲得超過13%的回報。
Expand
展開
NYSE: LLY
紐約證券交易所：LLY
Eli Lilly
禮來公司
Today's Change
今日變動
(2.87%) $34.47
(2.87%) 34.47美元
Current Price
目前價格
$1,234.53
1,234.53美元
Key Data Points
關鍵數據點
Market Cap
市值
$1.1TMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
1.1兆美元市值僅使用公開交易的流通股計算。不包括未上市、私有或雙類別非交易股份。隱含市值可能有所不同。市值僅使用公開交易的流通股計算。不包括未上市、私有或雙類別非交易股份。隱含市值可能有所不同。
Day's Range
日內範圍
$1223.70 - $1249.21
1,223.70美元 - 1,249.21美元
52wk Range
52週範圍
$623.78 - $1249.45
623.78美元 - 1,249.45美元
Volume
成交量
122.9K
12.29萬股
Avg Vol
平均成交量
3.3M
330萬股
Gross Margin
毛利率
82.83%
82.83%
Dividend Yield
股息殖利率
0.54%
0.54%
The healthcare titan's market capitalization has ballooned to more than $1.1 trillion, driven by the blockbuster success of its popular GLP-1 drugs, Mounjaro and Zepbound.
這家醫療保健巨頭的市值已膨脹至超過1.1兆美元，受其受歡迎的GLP-1藥物Mounjaro和Zepbound的巨大成功所推動。
Schott predicts that the rapid expansion of the U.S. weight-loss drug market and strong growth in international markets will drive Eli Lilly's sales and profits sharply higher.
肖特預測，美國減肥藥市場的快速擴張以及國際市場的強勁增長將推動禮來的銷售額和利潤大幅上升。
In turn, Schott expects the medicine maker's earnings to exceed consensus estimates when it reports its second-quarter financial results on Aug. 5.
反過來，肖特預期這家藥廠在8月5日公布第二季財報時，其獲利將超越市場共識預期。
Additional growth catalysts
額外成長催化劑
The obesity drug market is set to grow even larger. On July 1, the new GLP-1 Bridge program made Zepbound and Foundayo available to eligible Medicare patients for as low as $50 per month.
肥胖藥物市場將進一步擴大。7月1日，新的GLP-1 Bridge計畫使符合條件的聯邦醫療保險（Medicare）患者能以每月低至50美元的價格取得Zepbound和Foundayo。
With an estimated 20 million Medicare patients potentially meeting the criteria for obesity drugs, there's a good chance JPMorgan's $1,400 target price for Eli Lilly's shares proves conservative.
由於估計約有2,000萬名聯邦醫療保險患者可能符合肥胖藥物的條件，摩根大通對禮來股票設定的1,400美元目標價很可能被證明是保守的。